Dr. Janet Serle discusses the newest IOP-lowering glaucoma medications, including latanoprostene bunod or LBN, netarsudil, fixed-dose combination netarsudil/latanoprost, and the bimatoprost implant.

In this video, Dr. Angelo Tanna discusses what medication to add for a patient who needs a second medication to control intraocular pressure (IOP). He shares findings from a meta-analysis of randomized clinical trials assessing the IOP-lowering efficacy of alpha 2 adrenergic agonists, beta blockers, and carbonic anhydrase inhibitors, when added to a prostaglandin analog.

In this presentation from the AGS 2020, Dr. Ensign discusses sustained release methods to delivery ophthalmic drugs. She highlights developments in intraocular injections, sustained drug release and the use of prostaglandin.

This study assessed visual field outcomes in patients undergoing selective laser trabeculoplasty (SLT) versus medical therapy as a first-line treatment for ocular hypertension and glaucoma.

This learning plan, based on IRIS Registry measure IRIS2: Glaucoma IOP Reduction, discusses proper documentation of glaucoma patient treatment, clinical decision-making algorithms for glaucoma, and improving medication adherence in glaucoma patients.

Weekly case challenge

In this presentation from AGS 2019, we hear from one of Dr. Leon Herndon’s patients with advanced disease, followed by a discussion of creative approaches and the surgical management of these patients.

In this presentation from AGS 2019 leaders in glaucoma regenerative medicine discuss using stem cells and viruses to rejuvenate outflow, regenerating axons in the mature optic nerve and guiding those axons to their midbrain targets, and recent work on optic-nerve glymphatics in glaucoma.

In this 1-Minute Video, Dr. Tosin Smith offers pearls for identifying, managing and avoiding brimonidine-induced uveitis and conjunctivitis.